Boehringer Ingelheim and Carebox Healthcare Solutions have launched a digital platform aimed at giving patients, families, caregivers and doctors the opportunity to learn about the pharma company’s studies.
Carebox has expertise in study matching based on patient eligibility criteria and is working with the German pharma to help recruitment.
They said the MyStudyWindow follows a patient-centric approach using lay friendly language, educational content and user-friendly features.
Users can select from a range of condition-specific questionnaires to anonymously answer questions about a patient’s diagnosis, disease stage, and treatment history.
MyStudyWindow instantly matches the user to potentially relevant clinical studies from the Boehringer Ingelheim portfolio, suggests nearby study site locations, and provides guidance on contacting the site for next steps.
For studies that Boehringer Ingelheim would conduct in the future, patients will have the opportunity to provide feedback on their research experience to help the company tweak trials in the future to make them more appealing to patients.
Artificial intelligence automation continuously curates and structures the eligibility criteria for trials.
Increasing awareness of clinical trials is a challenge across industry, both with patients and doctors.
According to BI around 75% of investigators fail to enrol the target number of participants in trials, and 90% of all clinical trials fail to enrol patients within the target time and have to extend their enrolment period.
Mohammed Ali, Global Head of Digital Development, Global Clinical Operations at Boehringer Ingelheim, said: “This initial release of MyStudyWindow represents an important step towards our vision to bring patients and physicians closer to the clinical trials environment.
“We plan to establish a next-generation platform empowering patients who consider to participate in or to learn about Boehringer Ingelheim studies and research. In addition, we aim to support doctors to find the information they need to consult on and pursue a well-informed treatment.”
March 3, 2020